Literature DB >> 24474802

Remote loading of preencapsulated drugs into stealth liposomes.

Surojit Sur1, Anja C Fries, Kenneth W Kinzler, Shibin Zhou, Bert Vogelstein.   

Abstract

Loading drugs into carriers such as liposomes can increase the therapeutic ratio by reducing drug concentrations in normal tissues and raising their concentrations in tumors. Although this strategy has proven advantageous in certain circumstances, many drugs are highly hydrophobic and nonionizable and cannot be loaded into liposomes through conventional means. We hypothesized that such drugs could be actively loaded into liposomes by encapsulating them into specially designed cyclodextrins. To test this hypothesis, two hydrophobic drugs that had failed phase II clinical trials because of excess toxicity at deliverable doses were evaluated. In both cases, the drugs could be remotely loaded into liposomes after their encapsulation (preloading) into cyclodextrins and administered to mice at higher doses and with greater efficacy than possible with the free drugs.

Entities:  

Keywords:  MEK-1 inhibitor; PLK-1 inhibitor; nanoliposomes

Mesh:

Substances:

Year:  2014        PMID: 24474802      PMCID: PMC3926059          DOI: 10.1073/pnas.1324135111

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  72 in total

Review 1.  Clinical developments in nanotechnology for cancer therapy.

Authors:  Jeremy D Heidel; Mark E Davis
Journal:  Pharm Res       Date:  2010-06-12       Impact factor: 4.200

2.  Enhanced active liposomal loading of a poorly soluble ionizable drug using supersaturated drug solutions.

Authors:  Sweta Modi; Tian-Xiang Xiang; Bradley D Anderson
Journal:  J Control Release       Date:  2012-07-16       Impact factor: 9.776

Review 3.  Intracellular targeting delivery of liposomal drugs to solid tumors based on EPR effects.

Authors:  Kazuo Maruyama
Journal:  Adv Drug Deliv Rev       Date:  2010-10-28       Impact factor: 15.470

4.  The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1.

Authors:  Péter Lénárt; Mark Petronczki; Martin Steegmaier; Barbara Di Fiore; Jesse J Lipp; Matthias Hoffmann; Wolfgang J Rettig; Norbert Kraut; Jan-Michael Peters
Journal:  Curr Biol       Date:  2007-02-08       Impact factor: 10.834

5.  Phase i study of the Plk1 inhibitor BI 2536 administered intravenously on three consecutive days in advanced solid tumours.

Authors:  A Frost; K Mross; S Steinbild; S Hedbom; C Unger; R Kaiser; D Trommeshauser; G Munzert
Journal:  Curr Oncol       Date:  2012-02       Impact factor: 3.677

6.  Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles.

Authors:  Mark E Davis; Jonathan E Zuckerman; Chung Hang J Choi; David Seligson; Anthony Tolcher; Christopher A Alabi; Yun Yen; Jeremy D Heidel; Antoni Ribas
Journal:  Nature       Date:  2010-03-21       Impact factor: 49.962

Review 7.  Cyclodextrin-based supramolecular systems for drug delivery: recent progress and future perspective.

Authors:  Jianxiang Zhang; Peter X Ma
Journal:  Adv Drug Deliv Rev       Date:  2013-05-11       Impact factor: 15.470

8.  A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs.

Authors:  Y Matsumura; H Maeda
Journal:  Cancer Res       Date:  1986-12       Impact factor: 12.701

9.  A randomised phase II trial of the Polo-like kinase inhibitor BI 2536 in chemo-naïve patients with unresectable exocrine adenocarcinoma of the pancreas - a study within the Central European Society Anticancer Drug Research (CESAR) collaborative network.

Authors:  K Mross; C Dittrich; W E Aulitzky; D Strumberg; J Schutte; R M Schmid; S Hollerbach; M Merger; G Munzert; F Fleischer; M E Scheulen
Journal:  Br J Cancer       Date:  2012-06-14       Impact factor: 7.640

Review 10.  Tumor targeting using liposomal antineoplastic drugs.

Authors:  Jörg Huwyler; Jürgen Drewe; Stephan Krähenbuhl
Journal:  Int J Nanomedicine       Date:  2008
View more
  27 in total

1.  Pharmacokinetic stability of macrocyclic peptide triazole HIV-1 inactivators alone and in liposomes.

Authors:  Rachna Aneja; Antonella Grigoletto; Aakansha Nangarlia; Adel A Rashad; Steven Wrenn; Jeffrey M Jacobson; Gianfranco Pasut; Irwin Chaiken
Journal:  J Pept Sci       Date:  2019-02-27       Impact factor: 1.905

2.  A Simple and Improved Active Loading Method to Efficiently Encapsulate Staurosporine into Lipid-Based Nanoparticles for Enhanced Therapy of Multidrug Resistant Cancer.

Authors:  Wei-Lun Tang; Weihsu Claire Chen; Aniruddha Roy; Elijus Undzys; Shyh-Dar Li
Journal:  Pharm Res       Date:  2016-01-12       Impact factor: 4.200

Review 3.  Red blood cells: The metamorphosis of a neglected carrier into the natural mothership for artificial nanocarriers.

Authors:  Patrick M Glassman; Elizabeth D Hood; Laura T Ferguson; Zongmin Zhao; Don L Siegel; Samir Mitragotri; Jacob S Brenner; Vladimir R Muzykantov
Journal:  Adv Drug Deliv Rev       Date:  2021-09-29       Impact factor: 15.470

Review 4.  Biomimetic Exosomes: A New Generation of Drug Delivery System.

Authors:  Xudong Wang; Xian Zhao; Youxiu Zhong; Jiuheng Shen; Wenlin An
Journal:  Front Bioeng Biotechnol       Date:  2022-05-23

Review 5.  Polymer-Modified Liposomes for Drug Delivery: From Fundamentals to Applications.

Authors:  Yifeng Cao; Xinyan Dong; Xuepeng Chen
Journal:  Pharmaceutics       Date:  2022-04-02       Impact factor: 6.525

Review 6.  Membrane Organization Strategies in Vesicular Antibiotic Delivery.

Authors:  Paul R Meers
Journal:  J Membr Biol       Date:  2022-01-11       Impact factor: 2.426

Review 7.  Nanoplatforms for Targeted Stimuli-Responsive Drug Delivery: A Review of Platform Materials and Stimuli-Responsive Release and Targeting Mechanisms.

Authors:  Yuzhe Sun; Edward Davis
Journal:  Nanomaterials (Basel)       Date:  2021-03-16       Impact factor: 5.076

8.  Preloading of Hydrophobic Anticancer Drug into Multifunctional Nanocarrier for Multimodal Imaging, NIR-Responsive Drug Release, and Synergistic Therapy.

Authors:  Hui Wang; Kui Wang; Bowei Tian; Richard Revia; Qingxin Mu; Mike Jeon; Fei-Chien Chang; Miqin Zhang
Journal:  Small       Date:  2016-09-27       Impact factor: 13.281

9.  Cancer nanomedicines: oversold or underappreciated?

Authors:  Roy van der Meel; Twan Lammers; Wim E Hennink
Journal:  Expert Opin Drug Deliv       Date:  2016-11-28       Impact factor: 6.648

10.  Green Synthesis of Zr-Based Metal-Organic Framework Hydrogel Composites and Their Enhanced Adsorptive Properties.

Authors:  Shirell E Klein; Joshua D Sosa; Alexander C Castonguay; Willmer I Flores; Lauren D Zarzar; Yangyang Liu
Journal:  Inorg Chem Front       Date:  2020-09-25       Impact factor: 6.569

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.